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Objective To elucidate the common and distinct
clinical features of immune-mediated necrotising
myopathy (IMNM), also known as necrotising
autoimmune myopathy associated with autoantibodies
against signal recognition particle (SRP) and 3-hydroxy-
3-methylglutaryl-coenzyme A reductase (HMGCR).
Methods We examined a cohort of 460 patients with
idiopathic inﬂammatory myopathies (IIMs) through a
muscle biopsy-oriented registration study in Japan. Study
entry was strictly determined by the comprehensive
histological assessment to exclude other neuromuscular
disorders. Anti-SRP and anti-HMGCR antibodies were
detected by RNA immunoprecipitation and ELISA,
respectively.
Results Of 460 patients with IIM, we diagnosed 73
(16%) as having inclusion body myositis (IBM). Of 387
patients with IIMs other than IBM, the frequencies of
anti-SRP and anti-HMGCR antibodies were 18% and
12%, respectively. One patient had both autoantibodies.
Severe limb muscle weakness, neck weakness,
dysphagia, respiratory insufﬁciency and muscle atrophy
were more frequently observed in patients with anti-SRP
antibodies than in those with anti-HMGCR antibodies.
Serum creatine levels were markedly higher in the
patients with autoantibodies than in those without.
Histology was characterised by necrosis and regeneration
of muscle ﬁbres and was consistent with IMNM except
in 1 HMGCR-positive IBM patient. Most patients were
initially treated with corticosteroids; however, additional
immunosuppressive drugs were required, especially in
the patients with anti-SRP antibodies. Rates of
unsatisfactory neurological outcome were similar in the 2
autoantibody groups.
Conclusions Anti-SRP antibodies are associated with
severe neurological symptoms, more so than are anti-
HMGCR antibodies. Although these autoantibodies are
independent serological markers associated with IMNM,
patients bearing either share common characteristics.
INTRODUCTION
Inﬂammatory myopathies are a heterogeneous
group of subacute, chronic, or acquired diseases of
skeletal muscle.1 2 These myopathies involve skel-
etal muscle as well as many other organs, such as
the lungs, heart, joints and skin. Inﬂammatory
myopathies are the most commonly acquired
immune-mediated and potentially treatable muscle
diseases in children and adults. They are independ-
ently classiﬁed on the basis of distinct clinical or
histological criteria. In fact, among patients with
‘clinical’ polymyositis, only 5% have ‘histological’
polymyositis.3 This discrepancy may cause misinter-
pretation in general physicians. The clinical pheno-
types can be also deﬁned by certain autoantibodies
found in patients with inﬂammatory myopathies.4 5
It is of clinical importance to identify these auto-
antibodies because each autoantibody is closely
associated with certain clinical manifestations.
Over the last decade, immune-mediated necrotis-
ing myopathy (IMNM), also known as necrotising
autoimmune myopathy, has been recognised as a
category of idiopathic inﬂammatory myopathy
(IIM) characterised by necrosis in the absence of
prominent inﬂammatory cells.6 7 IMNM is
regarded as a different subtype from polymyositis,
dermatomyositis and inclusion body myositis
(IBM). The heterogeneous pathogenesis of necrotis-
ing myopathy includes autoantibody-mediated,
drug-induced and paraneoplastic disease, along
with overlap syndrome and viral infections.6–8
Autoantibodies against signal recognition particle
(SRP) or 3-hydroxy-3-methylglutaryl-coenzyme A
reductase (HMGCR) are regarded as representative
autoantibodies. Characteristic clinical manifesta-
tions associated with anti-SRP or anti-HMGCR
antibodies have been described,9–13 but they have
never been compared directly.
The purpose of the present study was to eluci-
date the common and distinct clinical features of
IMNM associated with anti-SRP and anti-HMGCR
antibodies among 460 patients with IIM through a
muscle biopsy-oriented registration study in Japan.
PATIENTS AND METHODS
We collected samples for the ‘Integrated Diagnosis
Project for Inﬂammatory Myopathies’ from
October 2010 to December 2014.14 We received
frozen muscle biopsy blocks and serum from
patients with tentative diagnoses of inﬂammatory
myopathies, from all over Japan. The following
study entry criteria were used: (1) the patient was
available for a muscle biopsy and could provide
serum, accompanied by full clinical information,
(2) the patient exhibited objective limb muscle
weakness supported by electromyography and/or
muscle MRI, (3) a diagnosis of inﬂammatory myop-
athies was made by a comprehensive histological
examination and (4) the patient signed an informed
consent agreement. This study was approved by the
Institutional Review Boards of both the National
Center of Neurology and Psychiatry, and Keio
University.
We enrolled 460 patients (male:female=201:
259; mean age at examination 55.2±20.8 years,
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range 2–84 years) with IIM by completely excluding other disor-
ders, which included muscular dystrophies, dysferlinopathy,
neurogenic muscular atrophy, clinically amyotrophic dermatomyo-
sitis, isolated neck extensor myopathy, glycogen storage disease,
mitochondrial myopathy, infectious myositis, sarcoid myopathy
and rhabdomyolysis, which were determined by clinical and histo-
logical assessment (see muscle histology section) (ﬁgure 1).
IBM was diagnosed by the identiﬁcation of rimmed vacuoles
with non-necrotic ﬁbres invaded by mononuclear cells or
increased major histocompatibility complex (MHC) class I
expression.15 Polymyositis was diagnosed based on endomysial
inﬂammation cell inﬁltrate surrounding or invading non-
necrotic muscle ﬁbres accompanied by ubiquitous MHC class I
expression. Dermatomyositis was diagnosed by the identiﬁcation
of the presence of perifascicular atrophy. IMNM was diagnosed
based on the observation of many necrotic ﬁbres as the predom-
inant abnormal histological feature without or with minimal
lymphocytes inﬁltration. Other myopathies were regarded as
non-speciﬁc myositis including perimysial and endomysial
inﬂammatory cell inﬁltration.16
Clinical features
Each patient’s clinical information was provided by his or her
referring physician, who completed detailed charts including clin-
ical course, neurological examination and laboratory ﬁndings. Skin
manifestations including Gottron’s rash and heliotrope sign were
regarded as skin rash.1 2 We additionally asked for follow-up infor-
mation of patients with anti-SRP or anti-HMGCR antibodies.
Neurological outcomes were assessed using the modiﬁed Rankin
Scale.10 Brieﬂy, patients who responded to the treatment and
returned to their jobs were deﬁned as 0 or 1. Patients who
responded partially to treatment and resumed most activities of
daily living were deﬁned as 2. Patients who responded minimally
to the treatment and required support in daily activities were
deﬁned as 3–5.
Muscle histology
All of the clinical materials used in this study were obtained for
diagnostic purposes with written informed consent. We pro-
cessed the skeletal muscle tissue for pathological analysis at
National Center of Neurology and Psychiatry.14 We stained
serial 10 μm thick cryosections using a battery of histochemical
methods including H&E, modiﬁed Gomori’s trichrome,
NADH-tetrazolium reductase, succinate dehydrogenase, cyto-
chrome C oxidase, periodic acid-Schiff, acid phosphatase, oil
red O, acetylcholinesterase, non-speciﬁc esterase, phosphorylase,
phosphofructokinase, alkaline phosphatase, AMP deaminase,
menadione-linked α-glycerophosphate dehydrogenase and
myosin ATPase. To exclude a range of muscular dystrophies, we
performed immunohistochemistry by using antibodies towards
dystrophin, α-sarcoglycans to δ-sarcoglycans, α-dystroglycans
and β-dystroglycans, dysferlin, caveolin-3, emerin, laminin α2,
collagen VI, p62 and CD8. In addition to the histological
studies, we performed mini-multiplex Western blotting using
antidystrophin, antidysferlin, anticalpain 3, anti-α-sarcoglycan
and antitelethonin.
We further analysed expression of MHC class I and II, and
membrane attack complex (MAC), in patients with anti-SRP and
anti-HMGCR antibodies. The patients whose muscle specimens
did not include more than 300 ﬁbres were excluded for this
analysis. For MHC class I and II, we judged as positive only
when the cytoplasm of non-necrotic/regenerating ﬁbres were
stained and negative if only sarcolemmata were stained. For
MAC, the presence of at least one non-necrotic ﬁbre with sarco-
lemmal deposits and that of at least one endomysial capillary
with MAC deposition were regarded as positive.
Autoantibody detection
All sera were obtained before the treatment initiation. Frozen
sera were stored at −30°C until use. Autoantibodies were
detected by RNA immunoprecipitation at Keio University by
researchers who were blind to the patients’ clinical and histo-
logical information.14 In addition, autoantibodies to HMGCR
were measured using an ELISA test.17 These detection assays
were performed in all samples, however, immunoblots or
dermatomyositis-associated autoantibodies were not evaluated
in all samples.
Statistical analyses
All analyses were performed using statistical analysis software
(IBM/SPSS V.20, Armonk, New York, USA). Comparisons of
relative frequencies were tested for signiﬁcance using the χ2 test
for 2×2 tables. Continuous variables were compared using the




Of 460 patients with IIM, we diagnosed 73 patients (16%) as
having IBM. Frequencies of autoantibodies are shown in table 1.
Anti-SRP antibodies were most frequently detected in 18% (69/
387) of the patients with IIMs other than IBM. Subsequently,
anti-HMGCR antibodies were found in 12% (46/387). In con-
trast, 13% (51/387) of patients possessed anti-aminoacyl transfer
RNA synthetase (anti-ARS) antibodies. These three autoanti-
bodies were found independently in all but one SRP/HMGCR
dual-positive patient. In no patient with IBM except one, who
had anti-HMGCR antibodies, were these three autoantibodies
detected. IIMs except for IBM (n=387) were further dividedFigure 1 Study ﬂow diagram. IIM, idiopathic inﬂammatory myopathy.
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into polymyositis (n=19), dermatomyositis (n=56), IMNM
(n=177), antisynthetase syndrome (n=51) and non-speciﬁc myo-
sitis (n=84), since anti-synthetase syndrome is a clinically and
pathologically distinct disease entity.18 19 Thus, anti-SRP and
anti-HMGCR antibodies were found in 39% (69/177) and 26%
(46/177) of the patients with IMNM.
Clinical features
To evaluate the characteristics associated with anti-SRP and
anti-HMGCR antibodies, we excluded two patients from the
analysis, the one patient with both antibodies and the one
patient with IBM with anti-HMGCR antibody. The resulting
clinical and laboratory examinations compared anti-SRP (n=68)
and anti-HMGCR (n=45) groups (table 2).
There were no signiﬁcant differences in the sex ratio and the
age at examination. Fully 18% of the anti-HMGCR group had
statin exposure, compared with 4% of the anti-SRP group
(p=0.019). Patients with stain exposure tended to be older than
those without in both groups (ﬁgure 2). Chronic progression of
muscle weakness over 12 months, which mimicked muscular
dystrophy, was observed equally in both groups.7 10 12
Fifty-three patients (63%) of the anti-SRP group showed severe
limb muscle weakness of grade ≤3/5 assessed by manual muscle
strength (Medical Research Council scale grade), compared with
11 patients (24%) of the anti-HMGCR group (p<0.0001). Limb
weakness usually affected legs more than arms. Laterality of limb
weakness was seen in 18% of the anti-SRP group and in 13% of
the anti-HMGCR group, respectively.
Neck weakness was found in 71% of the anti-SRP group,
which was signiﬁcantly higher than the corresponding value in
the anti-HMGCR group (p=0.0055). Dysphagia was also
highly detected in 68% of the anti-SRP group, compared with
44% of the anti-HMGCR group (p=0.014). Facial and cardiac
involvements were infrequent in both groups. Respiratory insuf-
ﬁciency was observed in 12% of the anti-SRP group, but in 0%
of the anti-HMGCR group (p=0.017). Muscle atrophy was
seen in 68% of the anti-SRP group, signiﬁcantly higher than the
percentage among the anti-HMGCR group (p=0.014).
The frequencies of extramuscular manifestations including
fever, skin rash, arthritis and Raynaud phenomenon, were low
in both groups. Interstitial lung disease in chest CT, observed in
19% of the anti-SRP group, was tentatively attributed to respira-
tory insufﬁciency. With regard to associated disorders, the fre-
quencies of cancer or concomitant rheumatic disease were not
signiﬁcantly different in the two groups.
Creatine kinase
Distribution of serum creatine kinase levels in all patients are
shown in ﬁgure 3. Serum creatine levels were equally markedly
elevated in the anti-SRP and anti-HMGCR groups. In contrast,
the serum creatine kinase level of the patients with IBM was
lower, at 632±458 IU/L. The serum creatine kinase level was
signiﬁcantly higher in the combined group of patients with
anti-SRP and anti-HMGCR antibodies than in those without
antibodies (6989±5034 vs 2764±6323 IU/L, p<0.0001). As
indicated in table 2, there were no differences in serum creatine
kinase level between the anti-SRP and anti-HMGCR groups.
On the other hand, the range of serum creatine kinase in the
ARS-positive patients was widely distributed: at an average of
4281±4981 IU/L.
Only one patient of the anti-SRP group and three patients of
anti-HMGCR group had serum creatine kinase levels under
1000 IU/L. When the cut-off level of serum creatine kinase level
was set as 1000 IU/L, the accuracy of the presence of anti-SRP
or anti-HMGCR antibodies in total patients with IIM including
IBM was calculated as 72%. In addition, 17 of 51 patients with
anti-ARS antibodies had serum creatine kinase levels under
1000 IU/L.
Table 2 Comparison between anti-SRP and anti-HMGCR
antibodies
Anti-SRP Anti-HMGCR
Findings, number (%) (n=68) (n=45) p Value
Female 40 (59) 31 (69) 0.28
Age at examination (years) 55.2±16.1 56.4±18.8 0.74
Statin exposure 3 (4) 8 (18) 0.019
Chronic progression 17 (25) 11 (24) 0.95
Muscle weakness
Legs dominant 52 (76) 32 (71) 0.52
Severe involvement 43 (63) 11 (24) <0.0001
Laterality 12 (18) 6 (13) 0.68
Distal dominant 1 (1) 0 (0) 0.41
Neck weakness 48 (71) 20 (44) 0.0055
Dysphagia 46 (68) 20 (44) 0.014
Facial involvement 3 (4) 1 (2) 0.54
Cardiac involvement 1 (1) 0 (0) 0.41
Respiratory insufficiency 8 (12) 0 (0) 0.017
Muscle atrophy 46 (68) 20 (44) 0.014
Decreased deep tendon reflex 31 (46) 15 (33) 0.19
Myalgia 27 (40) 10 (22) 0.052
Extramuscular symptoms
Fever 2 (3) 1 (2) 0.82
Skin rash 4 (6) 2 (4) 0.74
Arthritis 2 (3) 0 (0) 0.25
Raynaud phenomenon 4 (6) 0 (0) 0.098
Interstitial lung disease 13 (19) 3 (7) 0.063
Associated disorder
Cancer 4 (6) 2 (4) 0.74
Rheumatic disease 8 (12) 2 (4) 0.18
Blood examination
Creatine kinase (IU/L) 6589±4233 6436±4403 0.86
Elevated C reactive protein (≥1 mg/dL) 13 (19) 5 (11) 0.25
Antinuclear antibody positivity (≥1:160) 10 (15) 7 (16) 0.90
Histology
MHC class I upregulation 33/65 (51) 21/43 (49) 0.84
MHC class II upregulation 0/65 (0) 0/43 (0) NA
MAC deposition on sarcolemma 14/65 (22) 28/43 (65) <0.0001
MAC deposition on capillary 17/65 (26) 9/43 (21) 0.53
HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; MAC, membrane attack
complex; MHC, major histocompatibility complex; NA, not applicable; SRP, signal
recognition particle.
Table 1 Frequencies of autoantibodies
IBM IIM except for IBM
Number (%) (n=73) (n=387) p Value
Anti-SRP 0 (0) 69 (18) 0.00019
Anti-HMGCR 1 (1) 46 (12) 0.0066
Anti-ARS 0 (0) 51 (13) 0.001
Anti-U1RNP 2 (3) 20 (5) 0.37
Anti-Ku 0 (0) 16 (4) 0.077
Anti-SSA/Ro or SSB/La 8 (11) 43 (11) 0.97
ARS, aminoacyl transfer RNA synthetase; HMGCR, 3-hydroxy-3-methylglutaryl-
coenzyme A reductase; IBM, inclusion body myositis; IIM, idiopathic inflammatory
myopathy; SRP, signal recognition particle.
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In contrast, laboratory evaluation showed elevated C reactive
protein and antinuclear antibody positivity (≥1:160) were not
suggestive for the presence of anti-SRP or anti-HMGCR
autoimmunity.
Histological features
Histological features of patients with anti-SRP and
anti-HMGCR antibodies were characterised by necrosis and
regeneration of muscle ﬁbres, with no or little endomysial
lymphocyte inﬁltration (ﬁgure 4A). Necrotic ﬁbres are occasion-
ally associated with macrophage inﬁltration (ﬁgure 4A, B).
Results of immunohistochemical analysis of MHC class I and
II, and MAC, are represented in table 2. Increased expression of
MHC class I on cytoplasm of non-necrotic/regenerating ﬁbres
was observed in 33 of 65 (51%) patients with anti-SRP anti-
bodies and 21 of 43 (49%) patients with anti-HMGCR anti-
bodies. The stainability tended to be faint as compared with
other IIMs including polymyositis, dermatomyositis, and IBM.
Perifascicular reinforcement was observed in two anti-SRP
IMNM patients. No sample showed cytoplasmic upregulation
of MHC class II. Deposition of MAC on sarcolemma of non-
necrotic ﬁbres was more commonly seen in patients with
anti-HMGCR antibodies compared than in those with anti-SRP
(65% vs 22%, p<0.0001). The ﬁbres with sarcolemmal MAC
deposits were usually small-sized, but occasionally the surfaces
of apparently normal ﬁbres were also covered with MAC depos-
its. Deposition of MAC on endomysial capillaries was observed
in 17 of 65 (26%) patients with anti-SRP antibodies and 9 of
43 (21%) patients with anti-HMGCR antibodies. MAC depos-
ition on capillaries was sparse and less intense as compared with
that typically seen in dermatomyositis (data not shown).
Follow-up studies
Information regarding immunotherapy and neurological out-
comes of 51 SRP-positive patients and 39 HMGCR-positive
patients was available. Details of immunotherapy in the
anti-SRR and anti-HMGCR groups were compared (table 3).
Although corticosteroids were not administered in two
patients due to severe side-effects, the other 88 patients were
initially treated with corticosteroids. Some patients responded
well to corticosteroids, without or with minimal neurological
deﬁcit. The frequency of corticosteroid monotherapy was
higher in the anti-HMGCR group than in the anti-SRP group
(31% vs 8%, p=0.0048).
In the other patients, although the immunotherapy resulted
in a decrease of the patients’ creatine kinase levels, the recov-
ery of muscle weakness was insufﬁcient and they needed add-
itional immunotherapy. Administration of intravenous
immunoglobulin or intravenous methylprednisolone pulse
therapy was repeatedly performed in both groups. To avoid
side effects of corticosteroids, other additional immunosup-
pressive drugs were utilised. Among these drugs, tacrolimus
was preferentially selected more often in the anti-SRP group
than in the anti-HMGCR group (45% vs 13%, p=0.001).
Plasma exchange was also performed in two treatment-resistant
patients with anti-SRP antibodies.
The patients’ neurological outcomes assessed using the modi-
ﬁed Rankin Scale clearly showed incomplete improvement
(ﬁgure 5). There were no differences in neurological deﬁcits
between the anti-SRP and anti-HMGCR groups. Fifteen patients
(29%) of the anti-SRP group and nine (23%) of the
anti-HMGCR group suffered from difﬁculties in their daily
living graded as modiﬁed Rankin Scale scores 3–5.
Figure 3 Distribution of serum CK levels. CK, creatine kinase; IBM,
inclusion body myositis; IIM, idiopathic inﬂammatory myopathy;
HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; SRP, signal
recognition particle.
Figure 2 Distribution of onset age in 68 patients with anti-signal
recognition particle (anti-SRP) antibodies and 45 patients with
anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR)
antibodies.
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DISCUSSION
The present study’s ﬁnding can be summarised as follows: (1)
the frequencies of anti-SRP and anti-HMGCR antibodies in
patients with IIM except IBM were 18% and 12%, respectively;
(2) severe limb muscle weakness, neck muscle weakness, dyspha-
gia, respiratory insufﬁciency and muscle atrophy were more fre-
quently observed in the patients with anti-SRP antibodies than
in those with anti-HMGCR antibodies and (3) the rates of
unfavourable neurological outcome were similar in the two
groups of patients.
Previous studies reported that the frequencies of anti-SRP or
anti-HMGCR antibodies were 5–10% in patients with polymyo-
sitis and dermatomyositis.4 5 9–13 The frequencies of anti-SRP
and anti-HMGCR antibodies in the present study were higher
than in previous studies. The reason is due to differences in
study populations. The strength of our study is that study entry
was strictly determined by comprehensive histological assess-
ment in combination with Western blot—or, occasionally,
genetic analysis—to fully exclude neuromuscular disorders other
than IIM. In addition, the registration into the present project
was made mostly by neurologists or neuromuscular specialists
who manage patients with severe muscle weakness, which is
more common in IMNM than in classical polymyositis and
dermatomyositis. On the other hand, the frequency of anti-ARS
antibodies was lower in this cohort than in those in previous
studies. Anti-ARS antibodies, but not anti-SRP and
anti-HMGCR, can be routinely examined in Japan. The reason
for the lower frequency is that the patients proven to have
anti-ARS antibodies are encouraged to avoid muscle biopsy.
The detection of autoantibodies such as anti-ARS antibodies
and dermatomyositis-associated autoantibodies is useful for
diagnosis, determination of treatment strategy and prediction of
outcomes.4 5 In a like manner, anti-SRP and anti-HMGCR anti-
bodies are indispensable markers for IMNM, and also help dif-
ferentiate IMNM from muscular dystrophy.7 10 12 20 Serum
creatine kinase levels were markedly increased in patients with
these autoantibodies. These autoantibodies should be evaluated
early for patients with myopathy especially when serum creatine
kinase levels are elevated to >1000 IU/L.
We reported that the neurological outcome of SRP-positive
patients was unsatisfactory regardless of the combination of
immunosuppressive agents.21 In addition, the analyses revealed
that younger disease onset was the most signiﬁcant factor asso-
ciated with poor neurological outcome. Anti-HMGCR anti-
bodies were initially reported as a marker of statin-associated
myopathy.11 This subset usually affects older people and the
response to treatment is usually favourable. Subsequently, as
several independent groups have investigated the antibodies,
the ratio of statin-exposed patients among anti-HMGCR
antibody-positive patients has declined from 63–73% to 15–
44%, the latter consistent with the result of the present study
(18%).11–13 17 22 The lower frequencies may suggest that pro-
duction of anti-HMGCR antibodies is not directly related to
statin treatment. Although we considered the patients receiving
statin medication at symptom onset as statin-associated, the
possibility of coincidence was not fully excluded. In fact, statin
Figure 4 Muscle histology. (A) Necrotic (black arrow) and regenerating (arrowhead) ﬁbres. A white arrow indicates a necrotic ﬁbre with
macrophages (H&E stain). (B) Macrophages in necrotic ﬁbres are highlighted by acid phosphatase. Scale bar: 50 μm.
Table 3 Comparison of treatment
Anti-SRP Anti-HMGCR
Regimens, number (%) (n=51) (n=39)
p
Value
Corticosteroids 50 (98) 38 (97) 0.85
Corticosteroids alone 4 (8) 12 (31) 0.0048
Azathioprine 8 (16) 3 (8) 0.25
Methotrexate 4 (8) 5 (13) 0.44
Tacrolimus 23 (45) 5 (13) 0.001
Cyclosporine 7 (14) 3 (8) 0.37
Cyclophosphamide 2 (4) 1 (3) 0.72
Intravenous immunoglobulin 28 (55) 19 (49) 0.56
Intravenous methyl-prednisolone pulse
therapy
22 (43) 14 (36) 0.49
Plasma exchange 2 (4) 0 (0) 0.21
HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; SRP, signal recognition
particle.
Figure 5 Neurological outcomes using mRS. HMGCR,
3-hydroxy-3-methylglutaryl-coenzyme A reductase; mRS, modiﬁed
Rankin Scale; SRP, signal recognition particle.
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treatment is regarded as a risk factor of IMNM as well as of
cancer and connective tissue disease.8
Furthermore, since the present comparison of clinical proﬁles
of the patients with anti-SRP or anti-HMGCR IMNM in the
same cohort was performed, anti-SRP antibodies have been
shown to be more associated with severe limb muscle weakness
and frequent involvement of neck weakness, dysphagia, respira-
tory insufﬁciency and muscle atrophy.
While an obvious difference could be recognised on neither
conventional histochemistry nor on immunohistochemistry of
MHC class I and II, we noted that sarcolemmal MAC deposition
was more commonly seen in anti-HMGCR IMNM patients than
in those with anti-SRP. In prior studies, sarcolemmal MAC depos-
ition has been raised as a common pathological feature of
anti-HMGCR IMNM.12 23 24 Our study suggests that the MAC
deposition could be a characteristic feature of anti-HMGCR
NAM, however, these ﬁndings may be non-speciﬁc.
We are aware of a few study limitations. First, one conse-
quence of our integrated diagnosis project was that results of
autoantibodies were proven at different timings. We reported
the positivity of anti-SRP antibodies to each physician several
months after the start of treatment. The presence of anti-SRP
antibodies may be useful for physicians considering more
aggressive immunotherapy when their patients are not respond-
ing to corticosteroids. On the other hand, we only established
the detection system of anti-HMGCR antibodies in 2014.17
Thus, positivity of anti-HMGCR was not taken into consider-
ation in immunotherapy in our study. This study has demon-
strated that anti-HMGCR IMNM shows overall equivalence to
anti-SRP IMNM in terms of neurological outcome. However, if
the results of anti-HMGCR antibodies were available before
treatment initiation, neurological outcomes might have been
more favourable.
Second, duration of therapeutic regimens and time of
therapy initiation were varied in the present study. In add-
ition, there was no consensus on the regimens of immuno-
therapy. Therefore, we did not mention which agents were
more beneﬁcial to patients with anti-SRP/HMGCR IMNM.
Intravenous immunoglobulin was preferentially selected, as it
has been approved, by the Japanese government, for the treat-
ment of inﬂammatory myopathies. Among steroid-sparing
agents, mycophenolate mofetil, methotrexate and azathiopr-
ine, are generally administrated in the USA and in European
countries.8 12 In contrast, tacrolimus is frequently chosen in
Japan. This may be because physicians are familiar with the
use of tacrolimus in the treatment of other autoimmune dis-
eases. In this regard, rituximab is also a good candidate for
treatment-resistant patients.25 A double-blind and placebo-
controlled study is required to decide the best regimens of
immunotherapy for patients with anti-SRP/HMGCR IMNM.
Finally, it is important to conﬁrm the decreased levels of
anti-SRP and anti-HMGCR antibody titres over time under
treatment.9 26
In conclusion, anti-SRP antibodies were associated with a par-
ticular phenotype including severe muscle weakness and
atrophy, compared with anti-HMGCR antibodies.
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